ERBB2 and breast cancer: The first trial was an open-label, two-arm, phase III, randomized study to evaluate efficacy and safety of the 12-month CM maintenance regimen versus no CM after standard adjuvant chemotherapy for ER and PgR negative (<10 %) with any HER2 status of early breast cancer.